Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.37), $0.01 better than the analyst estimate of ($0.38).

“We are encouraged with our progress through the first half of 2018,” said Antony Mattessich, President and Chief Executive Officer. “The on-time resubmission and establishment of a December 28th PDUFA date for DEXTENZA® were critical achievements and we are pleased to have accomplished them. Clearly, we need to demonstrate that the transformation we have experienced internally translates to externally-validated results. While the team understands the approval of DEXTENZA is our top priority, we will continue to drive our pipeline forward which should be increasingly appreciated as we demonstrate our ability to execute.”

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.